Form 8-K - Current report:
SEC Accession No. 0001104659-20-108367
Filing Date
2020-09-25
Accepted
2020-09-24 17:59:06
Documents
7
Period of Report
2020-09-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2031738d1_8k.htm 8-K 18642
2 EXHIBIT 5.1 tm2031738d1_ex5-1.htm EX-5.1 8855
3 EXHIBIT 10.1 tm2031738d1_ex10-1.htm EX-10.1 197876
4 EXHIBIT 10.2 tm2031738d1_ex10-2.htm EX-10.2 77329
5 EXHIBIT 99.1 tm2031738d1_ex99-1.htm EX-99.1 7480
6 GRAPHIC tm2031738d1_ex5-1img001.jpg GRAPHIC 13638
7 GRAPHIC tm2031738d1_ex99-1.jpg GRAPHIC 6960
  Complete submission text file 0001104659-20-108367.txt   340059
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 201196235
SIC: 2836 Biological Products, (No Diagnostic Substances)